Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.

Open to people ages 18 years and up

• Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma
• Age ≥ 18 years
• Adequate renal function
• Adequate liver function
• Adequate hematological function
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

• Patients must not have clinically significant cardiac disease.
• Patients must not have known non-controlled CNS metastasis.
• Patients must not have active autoimmune disease or a documented history of autoimmune disease.
• Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
• Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.
• Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
• Patients must not be women who are pregnant or breast feeding.